The Latest Breaking News from Pfizer

Teen COVID boosters being considered

Case numbers of COVID-19 have been increasing across the country in recent days due to infections linked to an Omicron sub-variant.

AAP · Mar 28, 2022

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

Benzinga · Mar 28, 2022

Antiviral drug to be trialled in hospitalised Covid patients

Having already been approved for early-stage treatment of Covid, scientists will now assess how Paxlovid performs when administered to people hospitalised with infection

The Independent UK · Mar 28, 2022

Covid vaccinations in US fall to lowest level since 2020

Public health experts say the low number of Americans receiving booster shots is an ‘unforgivable liability’

The Independent UK · Mar 26, 2022

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

StockNews.com · Mar 25, 2022

FDA advisory panel to discuss Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK · Mar 25, 2022

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK · Mar 24, 2022

Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults

The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE:PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy…

Benzinga · Mar 24, 2022

Fosun Reports $157 Million of China mRNA Vaccine Sales in 2021

BioNTech partner markets the advanced-tech inoculation in Hong Kong, Macao and Taiwan as regulators haven’t cleared the shots for the mainland

Caixin Global · Mar 23, 2022

EXPLAINER: What to know about COVID vaccines for little kids

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

The Independent UK · Mar 23, 2022